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sotretinoin is used widely to treat severe and scarring cystic acne. The drug was first approved for use in Canada in 1983. It is a potent teratogen, 1, 2 and female users should avoid pregnancy during and for at least 1 month after the end of treatment. 3 Isotretinoin exposure can lead to a range of severe craniofacial, cardiac and central nervous system abnormalities and may also lead to increased rates of spontaneous and elective abor tion. [1] [2] [3] The average age of isotretinoin users in Canada is estimated to be 24 years, and half of all prescriptions are written for female patients. 4 Although the risks of pregnancy during isotretinoin therapy have been recognized for more than 30 years, repeated studies have shown poor adherence to pregnancy prevention guide lines in several countries, including Canada. [3] [4] [5] [6] [7] [8] Several factors may have increased the prob ability of inadvertent exposure. The first is the marketing of several generic products by com panies that may not have the prescriber and consumer education resources of the original manufacturer. 9 The second is a rapid increase in use of the drug and a shift to prescribing isotre tinoin for milder forms of acne. 10 The latter was reflected in a populationbased study in Que bec, in which 64% of firsttime isotretinoin recipients did not have a history of having used Methods: Using administrative data, we identi fied 4 historical cohorts of female users of isotretinoin (aged 12-48 yr) for the period 1996 to 2011. We defined pregnancy using Interna tional Statistical Classification of Diseases and billing codes. One definition included only cases with documented pregnancy outcomes (high specificity definition); the other definition also included individuals recorded as receiving pre natal care (highsensitivity definition). We stud ied new courses of isotretinoin and detected pregnancies in 2 time windows: during isotre tinoin treatment only and up to 42 weeks after treatment. Live births were followed for 1 year to identify congenital malformations.
Results:
A total of 59 271 female patients received 102 308 courses of isotretinoin. Between 24.3% and 32.9% of participants received prescriptions for oral contraceptives while they were taking isotretinoin, compared with 28.3% to 35.9% in the 12 months before isotretinoin was started. According to the highspecificity definition of pregnancy, there were 186 pregnancies during isotretinoin treatment (3.1/1000 isotretinoin users), com pared with 367 (6.2/1000 users) according to the highsensitivity definition. By 42 weeks after treatment, there were 1473 pregnancies (24.9/1000 users), according to the high specificity definition. Of these, 1331 (90.4%) terminated spontaneously or were terminated by medical intervention. Among the 118 live births were 11 (9.3%) cases of congenital mal formation. Pregnancy rates during isotre tinoin treatment remained constant between 1996 and 2011.
other antiacne medications, a breach of pre scribing guidelines. 7 The risk of exposure may have been further increased by online availabil ity of multiple isotretinoin products without prescription or proper risk information.
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The teratogenic effects of isotretinoin are preventable, and there have been numerous attempts to minimize the risk of pregnancy dur ing treatment. Since teratogenicity was first documented in humans, the Dermatologic and Ophthalmic Drugs Advisory Committee of the US Food and Drug Administration (FDA) has made frequent recommendations to balance the needs of patients with severe acne with the imperative to prevent fetal exposure. 12 Central to these efforts has been a worldwide, sponsor developed Pregnancy Prevention Program launched in 1988. 12 Following the introduction of generic isotretinoin products in 2002, the FDA launched an integrated risk management program for all isotretinoin products in 2006. 13 As part of this mandatory program (known as iPLEDGE; www.ipledgeprogram.com) patients must register, complete an informed consent form and receive counselling about the risks associated with the drug, and women of child bearing age must comply with required preg nancy testing. Only registered prescribers and pharmacists are permitted to prescribe and dis pense isotretinoin.
Canada has not adopted a program equiva lent to iPLEDGE. The program that is in place in Canada requires informed written consent, 2 pregnancy tests with negative results before starting isotretinoin and 2 reliable forms of con traception during treatment. 3 Health Canada periodically reviews the pregnancy prevention program with manufacturers. Isotretinoin use and pregnancy have been studied in Quebec 7 and through counselling services, 5 but there has been no populationbased study of isotretinoin use and pregnancy outcomes in a large and rep resentative sample of isotretinoin users in Can ada. As part of a review of its isotretinoin preg nancy prevention program, Health Canada asked the Canadian Network for Observational Drug Effect Studies (www.cnodes.ca), part of the Drug Safety and Effectiveness Network (www.cihrirsc.gc.ca/e/40269.html), to report on the frequency of pregnancy during isotre tinoin use in several Canadian provinces and the outcomes of these pregnancies.
The objectives of this study were to estimate the frequency of pregnancy during and immedi ately after treatment with isotretinoin, the num ber of potentially exposed pregnancies that go to term, the number of resulting fetal abnormal ities and whether these rates have changed over time. We studied the use of oral contraceptives, both concomitant with isotretinoin therapy and in the year before treatment, and also estimated the proportions of female isotretinoin users who had tried alternative acne treatments before commencing their first course of isotretinoin.
Methods
This retrospective cohort study included all female patients aged 12-48 years, in 4 prov inces, for whom one or more prescriptions for isotretinoin were dispensed between 1996 and 2011. We analyzed linked administrative health datasets from British Columbia, Saskatchewan, Manitoba and Ontario (combined population 20.7 million). In Ontario, coverage for isotreti noin was limited to those receiving social assis tance. In BC, Saskatchewan and Manitoba, cov erage was more comprehensive.
Pregnancies were identified using both hospi tal separation records and medical services insurance data, on the basis of diagnostic codes from the International Classification of Dis eases, 9th revision (ICD9) and the International Statistical Classification of Diseases and Related Health Problems, 10th revision, enhanced Can adian version (ICD10CA), as well as provin cial medical services procedure codes (see Appendix 1, available at www.cmaj.ca/lookup/ suppl/doi:10.1503/cmaj.151243//DC1). We studied only pregnancies that occurred during isotretinoin treatment or that could be reason ably assumed to have had exposure.
All of the analyses were conducted with de identified data. The study was reviewed and approved by research ethics bodies in each of the 4 provinces. Further details are provided in Appendix 2, available at www.cmaj.ca/lookup/ suppl/doi:10.1503/cmaj.151243//DC1.
Cohort entry
Female patients were included in the cohort when they began an episode of isotretinoin therapy dur ing the study period. All residents covered by their respective provincial drug insurance pro grams for at least 12 months before the start of the study were eligible for inclusion. Patients who had multiple episodes of drug use were entered into the cohort more than once. A series of prescriptions was considered a continuous epi sode of drug therapy if a prescription was filled within the time period between the previous pre scription fill date plus the number of days' supply dispensed in the previous prescription plus 30 days. If the time between prescription refills was longer, the patient was reentered into the cohort at the time of the next episode of use.
Definition of exposure
Fetal exposure to isotretinoin was defined as occurring when the date of a valid diagnostic or procedure code for pregnancy (see Appendix 1) fell within the dates covered by the isotretinoin prescriptions dispensed to an individual. This definition will have underestimated the true exposure rates because the first record of a diagnostic code (e.g., spontaneous abortion or birth) may have been after the cessation of isotretinoin treatment and therefore not counted under this definition.
A range of followup periods were considered, all of which increased the apparent rate of exposed pregnancies beyond the base case assumption; however, they all included potential exposure later in pregnancy when the fetus would not have been at maximum risk (where the period of maximum risk was defined as the first 4 weeks after conception). To address the problem of underestimation of overall exposure, and to study all pregnancy outcomes, we also documented any relevant diagnostic code with a date that fell within the period of isotretinoin treatment and, in the case of births, up to 42 weeks after the end of treatment. Spontaneous and induced abortions were included if they occurred within 26 weeks after treatment ended or within 22 weeks of the 1month "washout period."
Identification of pregnancies
In an era of selfadministered pregnancy tests, identification of pregnancy in administrative data is challenging. 14, 15 With the exception of births, gestational age could not be determined, given that the onset of pregnancy was not docu mented in the administrative health databases, and the majority of pregnancies were termin ated. Two sets of diagnostic and procedural codes were used to estimate the occurrence of pregnancy during treatment (Appendix 1). The more conservative approach (highspecificity definition) included only those diagnostic codes for pregnancy outcomes (i.e., abnormal prod ucts of conception, spontaneous or medical abortions, live births or stillbirths).
Recognizing that many participants will have experienced early pregnancy losses not captured by administrative health databases, a second, broader definition was operationalized, which included diagnostic codes for care provided pri marily in medical clinics (e.g., supervision of highrisk pregnancy). These diagnoses allowed us to identify not only early pregnancy losses, but also mothers who may have completed their pregnancy out of hospital or out of province.
Both hospital discharge abstracts and provin cial health insurance (medical billing) data were used to identify the diagnostic codes of interest (Appendix 1). Relevant billing codes were added to better capture care provided in clinics. As an example, Appendix 1 lists relevant procedure codes from one provincial insurance plan (Sas katchewan). Equivalent codes were used for the other 3 provinces. Pregnancy outcomes were grouped as follows: live births, stillbirths, live births with congenital malformations, induced abortions (including pregnancy terminations due to fetal abnormalities) and spontaneous abor tions. Births were subsequently validated using vital statistics birth registration files.
All pregnancy cases were reviewed manually by researchers at each site to ensure that none was counted more than once and that care codes linked to a later pregnancy outside the exposure period were removed. Hospital, medical services and birth registration data were used together to identify documented cases of congenital malfor mations in live or stillborn infants. In the case of pregnancy terminations following prenatal diag nosis, certain diagnostic codes enabled the identi fication of anomalies (ICD9 codes 655.0, 655.1, 655.5, 655.9; ICD10CA codes O35.0, O35.1, O35.5, O35.9).
Results

Characteristics of participants and treatment courses
In total, there were 59 271 female isotretinoin users in the relevant age group who received 102 308 courses of isotretinoin in BC, Sas katchewan, Manitoba and Ontario between 1996 and 2011. Most were urban dwellers with mean ages (by province) ranging from 22.9 to 26.7 years. The median duration of therapy in one course varied from 68 days in Ontario to 113 days in Manitoba (see Table 1 for addi tional details on characteristics of participants and treatment courses). Social status data were not available for all 4 provinces. In Ontario, 89.5% of participants (3897/4355) were recorded as welfare recipients, who tended to be older and took shorter courses of treatment than isotretinoin users in the other provinces.
Concomitant and prior use of oral contraceptives and other acne drugs
The use of oral contraceptives in the 12 months before entering the cohort ranged from 28.3% in Ontario to 35.9% in BC (Table 2) . By compari son, use of oral contraceptives during isotretinoin therapy was not higher, ranging from 24.3% in Saskatchewan to 32.9% in Manitoba. Use of other acne drugs before isotretinoin treatment ranged from 45.4% in Ontario to 72.0% in BC.
Pregnancies recorded during and after the treatment period
Depending on the definition (highspecificity v. highsensitivity), overall pregnancy rates during isotretinoin treatment ranged from a low of 1.7 per 1000 female isotretinoin users (Saskatche wan, highspecificity definition) to a high of 18.6 per 1000 users (Ontario, highsensitivity defini tion) (Table 3 ). Rates were generally higher in the Ontario cohort. In the other provinces, they were in the range of 2-3 per 1000 users (high specificity definition) to 4-6 per 1000 users (highsensitivity definition). Although we differ entiated the code lists, the codes for the high sensitivity definition were actually quite specific for pregnancy and unlikely to lead to many false positives (Appendix 1). As such, the latter figure of 4-6 per 1000 users probably best represents the pregnancy rates for typical users of isotreti noin in Canada. It should be noted that this value is conservative, given that it includes only preg nancies that occurred during the period of active isotretinoin treatment.
When we pooled data from the 4 provinces using the codes for the highsensitivity defini tion, there was no evidence of changes over time in rates of pregnancy during isotretinoin treatment: 5 per 1000 isotretinoin users between 1996 and 1999, 4 When the followup period was extended to the treatment period plus 42 weeks, the esti mated pregnancy rates were, on average, 42.3 per 1000 isotretinoin users (highsensitivity def inition), ranging from 21.7 per 1000 users in Saskatchewan to 116.9 per 1000 users in Ontario. Because of the exposure time window, these are effectively annual rates of pregnancy.
Pregnancy outcomes
The widened exposure time window (treatment plus 42 weeks) enabled us to study pregnancy outcomes (Table 4) . Over the 15 years of the study, 1473 pregnancies were recorded (using 
Interpretation
This study of data from 4 Canadian provinces documented consistent occurrence of pregnancy during treatment with isotretinoin. Rates were highest in Ontario, among a cohort receiving social assistance. Higher rates of pregnancy among isotretinoin users from lower socio economic groups has previously been reported for Quebec. 7 Using the rates documented in the other provinces as a more representative value, and including both highspecificity and high sensitivity definitions, we estimate that between 4 and 6 per 1000 female isotretinoin users con ceive while taking a 3month course of isotreti noin in Canada. A systematic review of data from pregnancy prevention programs in Europe documented pregnancy rates of between 0.2 and 1 per 1000 female isotretinoin users. 8 However, differences in methods prevent a direct compari son of these rates. The European review found that the majority of exposed pregnancies were terminated, as was the situation in this study.
From the rates of pregnancy documented dur ing isotretinoin use, we can estimate an annual pregnancy rate during treatment of 16 to 24 per Note: BC = British Columbia, TOPFA = termination of pregnancy for fetal abnormality. *For 2 cases in Manitoba, the outcome could not be categorized because of smallcell suppression rules. †For 22 cases in Ontario, no pregnancy outcome was documented. ‡includes spontaneous abortions and a very small number of stillbirths. §Data suppressed to protect patient confidentiality. ¶The cases with outcome of congenital malformation (n = 11) represented 0.7% of all pregnancies and 9.3% of live births.
1000 female users. From Statistics Canada data for the relevant age group, we estimate an annual unplanned pregnancy rate of about 50 per 1000 female patients. 16 These estimates imply that contraceptive measures during isotretinoin treat ment in Canada are achieving an effectiveness of about 50% to 70%, short of the ideal when a potent teratogen is being ingested.
There was a large difference in the number of pregnancies identified between the narrow and wide time windows for exposure, whether identified by the highspecificity or the high sensitivity definition. Using the highspecificity definition, we estimated that the pregnancy rate in the cohort during the first 90 days was about 2 per day, compared with a rate of more than 4 per day in the subsequent 294day (42week) followup period, after treatment stopped. We assume that some individuals relaxed their con traceptive measures after ceasing isotretinoin and that this accounts for the higher rate in the latter phase of the followup period. Many in the latter group were probably not exposed during a theoretically vulnerable exposure period for the fetus and, as noted, we could not obtain gesta tional age. Most of the pregnancies were termin ated anyway, which indicates that isotretinoin treatment had both major direct and major in direct effects on the course of these pregnancies.
Of 118 live births with fetal exposure to isotretinoin over the period 1996 to 2011, 11 (9.3%) were recorded as having congenital mal formations. A crude scaling of these estimates to the population of Canada suggests that 1 or 2 children are born with congenital anomalies each year after maternal use of isotretinoin. We do not know the severity of these abnormalities or whether the relation with isotretinoin is causal. Rates of major congenital abnormalities among live births in Canada are reportedly in the range of 3% to 5%. 17 We are not comparing this rate with what we observed among isotretinoin users, given that our purpose was not to measure the association between isotretinoin use and fetal abnormality. This association is well known.
1,2 It is likely that diagnostic ultrasound examinations were performed for some of the pregnancies documented here and that the findings led to a decision to terminate the pregnancy.
The rates of concomitant use of oral contra ceptives that we documented were rather low. We may have underestimated this value because of individuals who received prescrip tions for oral contraceptives privately, directly from their doctor or from family planning ser vices, or who had an extensive supply from a prescription issued outside the time period cov ered by our records. However, these caveats also apply to the measurement of oral contra ceptive use in the 12 months before isotretinoin treatment, and the 2 rates of use appeared simi lar. We also concede that we did not document the use of intrauterine devices and cannot deter mine the use of barrier methods. The Canadian recommendations require 2 negative pregnancy test results before and use of 2 reliable forms of contraception during and until at least 1 month after isotretinoin treatment. 18 Clearly there is incomplete compliance with this standard, as reflected by the low use of oral contraceptives and the constant pregnancy rate over the period of this study.
Our findings are in line with the literature. Failure to use adequate contraception is, predict ably, the leading reason for pregnancy during isotretinoin treatment. Internationally, between 7% and 60% of female users have been found not to use any form of contraception during treatment. 19, 20 As many as 80% do not use 2 methods of birth control, as recommended. 21 Another area of poor adherence with prescrib ing advice is the use of less restricted and safer treatments for acne before graduating to isotreti noin. In this study, between 45.4% and 72.0% of isotretinoin users had received prescriptions for other acne treatments in the previous year, with the lowest rate in the Ontario cohort. This obser vation and the low use of oral contraceptives point to clear areas for improvement in the man agement of acne and isotretinoin therapy.
Several studies in the US, Canada and Europe have documented low use of effective contracep tion, low compliance with pregnancy prevention programs, birth defects from in utero exposure and high rates of termination of pregnancy after maternal isotretinoin use. [5] [6] [7] [8] [22] [23] [24] One study reported a risk of becoming pregnant while taking isotretinoin of 8 per 1000 personyears of treat ment. 22 This is lower than the annual rate calcu lated for Canada and is likely to be an underesti mate because of underreporting to voluntary registries. More relevant to our results is the study in Quebec, which covered the period from 1988 to 2002 and reported a rate of 10.5 per 1000 isotre tinoin users, 7 somewhat higher than our estimate of 4-6 per 1000 users, but closer to the rate seen in the Ontario cohort. In the Quebec study, the researchers used a broader selection of pregnancy codes, including perinatal and fetal complications, and also included patients who were pregnant when they started treatment. 7 Eightyfour percent of pregnancies were terminated, similar to what we found for BC but higher than the 4province average of 70.7% reported here. Among 90 exposed pregnancies in the Quebec cohort, there were 9 live births, one with major malformations. 7 
Limitations
There are important limitations to this work, some of which have already been discussed. For example, as noted earlier, we did not have access to the results of pregnancy tests and instead used a combination of diagnostic and insurance codes. Even our highsensitivity definition of pregnancy was more restrictive than that used in the Quebec study, which may have led to us to underestimate the rate of exposed pregnancies. We used a con servative time window to identify pregnancies detected only during active treatment with isotre tinoin. For this reason, we also performed analy ses with a widened time window of 42 weeks after cessation of isotretinoin, with the additional aim of following potentially exposed pregnancies to term. Although this approach probably led us to include conceptions that occurred outside a vulnerable period of fetal exposure, it is notable that more than 70% of the pregnancies were ter minated medically, and for BC, this figure was even higher. This implies that both the patients and their health care professionals were con cerned about the possibility of fetal exposure to isotretinoin or had ultrasound evidence of fetal abnormality.
Because we relied on administrative data, we cannot be sure that female patients for whom isotretinoin was dispensed actually took the drug. Finally, the most recent data are now quite dated (up to 2011 only), because of delays in access to data in one province. However, the rates of pregnancy were consistent over a 15year period, and we doubt that access to more recent data would change our main conclusions.
Conclusion
There was surprising consistency in pregnancy rates during isotretinoin treatment between 1996 and 2011, despite the Canadian pregnancy prevention program. US studies have shown that the impact of the iPLEDGE program also appears to have been modest in terms of increased uptake of oral contraceptives and reduced numbers of exposed pregnancies. 23, 24 It is clear from this experience and from studies in Europe that modifying contraceptive behav iour in this setting is difficult. Nevertheless, medical practitioners and patients must be con stantly reminded of the risks of isotretinoin to the fetus and must adhere to the policy that mandates effective contraceptive measures.
